FDA authorises Forward Science’s Orapeutic gel

Forward Science’s (FS) Orapeutic gel, developed to relieve oral pains including, mouth sores, wounds and ulcers, has been authorised by the Food and Drug Administration (FDA). The non-opioid gel’s purpose is to prevent any further infection or displeasure in the mouth by sticking to the oral tissue and establishing a protective layer between the wound.

Brian Pikkula, Phd – Chief Technology Officer and Co-Founder of Forward Science, stated: “We are proud of our previously released products and their impact on the healthcare industry but our R and D team is always striving to develop products that meet market demands. With the success of our previous product launches we have become the industry’s leader of innovative solutions in oral healthcare. We are thrilled to receive FDA clearance for Orapeutic and are looking forward to hearing from clinicians as to how this product impacts their patients.”